Hydrocortisone Zentiva Pharma

Hydrocortisone Zentiva Pharma is an oral corticosteroid medication containing hydrocortisone as the active ingredient. It is supplied in tablet form (strength not specified) and marketed in the European Union. The product belongs to the glucocorticoid therapeutic class and is used under medical supervision for conditions requiring glucocorticoid replacement or anti‑inflammatory therapy. It is regulated as a prescription product in most EU member states and follows standard pharmaceutical quality standards.

Hydrocortisone Zentiva Pharma is prescribed for several endocrine and inflammatory conditions where glucocorticoid activity is required.

- Replacement therapy for primary or secondary adrenal insufficiency. - Management of congenital adrenal hyperplasia. - Adjunct treatment of inflammatory or autoimmune disorders such as rheumatoid arthritis. - Short‑term control of severe allergic reactions when oral steroids are indicated. - Supportive therapy during stress dosing for patients on chronic glucocorticoids. - Temporary suppression of endogenous cortisol production in diagnostic testing protocols.

Oral hydrocortisone may cause a range of adverse reactions, varying from mild to severe.

Common: - Increased appetite and weight gain. - Fluid retention leading to mild edema. - Elevated blood pressure. - Mood changes such as irritability or anxiety. - Gastrointestinal discomfort, including nausea or dyspepsia. - Skin thinning and easy bruising. - Insomnia or sleep disturbances. - Acne or worsening of existing acne.

Serious: - Severe hyperglycemia or new‑onset diabetes. - Suppression of the hypothalamic‑pituitary‑adrenal axis. - Opportunistic infections due to immunosuppression. - Osteoporosis with increased fracture risk. - Peptic ulcer disease or gastrointestinal bleeding. - Cushingoid appearance with facial rounding. - Psychiatric disturbances such as psychosis or severe depression.

Before initiating Hydrocortisone Zentiva Pharma, clinicians should evaluate several safety considerations to minimize risk.

- Assess baseline blood glucose and monitor for hyperglycemia during therapy. - Screen for active infections; treat before starting systemic glucocorticoids. - Evaluate bone health, especially in patients with osteoporosis risk factors. - Use the lowest effective dose for the shortest duration possible. - Counsel patients on signs of adrenal insufficiency during dose tapering. - Review pregnancy and lactation status, as glucocorticoids cross the placenta.

Hydrocortisone can alter the pharmacokinetics or pharmacodynamics of other medicines; certain combinations should be avoided or used with caution.

Avoid: - Strong CYP3A4 inducers such as rifampin, which may reduce hydrocortisone exposure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase gastrointestinal bleeding risk. - Anticoagulants (e.g., warfarin) where glucocorticoids may enhance anticoagulant effect.

Use with caution: - Antidiabetic agents, as hydrocortisone may raise blood glucose levels. - Vaccines, particularly live attenuated vaccines, due to immunosuppression. - Diuretics, which can exacerbate fluid retention and electrolyte imbalance.